Daniel E. Furst
University of California, Los Angeles · 568 works · 50,410 citations · h-index 98
Top works
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
- 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis
- Cyclophosphamide versus Placebo in Scleroderma Lung Disease
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
- Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
- Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
- Low‐Dose D‐Penicillamine Therapy in Rheumatoid Arthritis
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- Reduced joint counts in rheumatoid arthritis clinical trials
- Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis
- Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
- 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis
- Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
- High versus low dosing of oral colchicine for early acute gout flare: Twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison colchicine study
- Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development